Activity-Based Intervention to Address Cannabis Use

September 9, 2026 updated by: Erin Bonar, University of Michigan

A Remote Behavioral Economics-Based Intervention for Cannabis Use Disorder: Bridging Gaps in Care

This study is being completed to test a method to promote patient-centered outcomes among people who use cannabis behaviors.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

300

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan, Ann Arbor, Michigan 48109
        • Principal Investigator:
          • Erin Bonar, PhD
        • Contact:
        • Principal Investigator:
          • Lara Coughlin, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • current cannabis use disorder
  • active cannabis use,
  • camera/technology/phone access
  • able to give informed consent.

Exclusion Criteria:

  • inability to speak English
  • conditions precluding informed consent, full participation, or understanding of interventions/assessments
  • past 90-day cannabis use disorder/substance use disorder treatment
  • current cancer treatment
  • medical cannabis certification for current cancer, end-of-life care, or progressive debilitating disease
  • active moderate/severe other substance use disorder(s) or injection drug use

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MI-BE
Behavioral: Motivational and Behavioral Economics Informed Intervention
6 session telemedicine-delivered intervention with coaching sessions and small incentives for activity engagement.
Active Comparator: EUC
Behavioral: Enhanced Usual Care
Brief psychoeducation and referral resources

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cannabis use
Time Frame: 3-, 6-, 12-months
Change in frequency of cannabis use measured by the Timeline Follow Back
3-, 6-, 12-months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cannabis use disorder symptoms
Time Frame: 3-, 6-, 12-months
Change in cannabis use disorder symptoms measured by the Diagnostic & Statistical Manual-5 checklist where higher scores indicate a worse outcome (0 min score, 11 max score)
3-, 6-, 12-months
Depressive symptoms
Time Frame: 3-, 6-, 12-months
Change in depression symptom severity as measured by Patient Health Questionnaire-where higher scores indicate a worse outcome (min score = 0, max score = 24)
3-, 6-, 12-months
Anxiety symptoms
Time Frame: 3-, 6-, 12-months
Change in anxiety symptom severity as measured by Generalized Anxiety Disorder-7 questionnaire where higher scores indicate a worse outcome (min score = 0, max score = 21)
3-, 6-, 12-months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Michigan

Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Lara Coughlin, PhD, University of Michigan
  • Principal Investigator: Erin Bonar, PhD, University of Michigan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2027

Primary Completion (Estimated)

September 1, 2030

Study Completion (Estimated)

September 1, 2030

Study Registration Dates

First Submitted

September 4, 2026

First Submitted That Met QC Criteria

September 4, 2026

First Posted (Actual)

September 10, 2026

Study Record Updates

Last Update Posted (Actual)

September 14, 2026

Last Update Submitted That Met QC Criteria

September 9, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • HUM00291757
  • R01DA062399 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe